Skip to content
DataLookout
Menu

NCT02736656

Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved at least 2 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 11 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 23 words Show 4 more changesShow less
    • Primary and study completion pushed from Sep 2026 to Dec 2026
    • Secondary endpoints: details revised at 1 of 2 entries
    • Site details revised at 2 of 16 sites
    • Publications: details revised at 1 of 1 entry
  2. Minor Study description expanded, about 12 wordsv10
  3. Notable Eligibility criteria expanded, about 191 words
    • Secondary endpoints revised (2)
    • Study description expanded, about 9 words
    v9
  4. Notable Primary and study completion dates: Jun 2025 to Sep 2026v8 Show 4 more changesShow less
    • Eligibility criteria expanded, about 35 words
    • Enrollment target: 1200 to 1400
    • Study description shortened, about 23 words
    • Study title revised
  5. Notable Primary and study completion dates: Jun 2024 to Jun 2025v7
Show 5 earlier versionsHide 5 earlier versions
  1. Minor Interventions: SPN-812 ER (Drug) to SPN-812 (Drug)v6
  2. Notable Primary and study completion dates: Jun 2021 to Jun 2024
    • Eligibility criteria expanded, about 117 words
    • Secondary endpoints revised (2)
    • Study description expanded, about 11 words
    v5
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Secondary endpoints: details revised at 1 of 2 entries
    • Site details revised at 16 of 16 sites
    v4
  4. Notable Enrollment target: 200 to 1200v3 Show 6 more changesShow less
    • Primary and study completion dates: Apr 2019 to Jun 2021
    • Eligibility criteria revised
    • Study sites: 1 to 16
    • Start date: Apr 2016 to Feb 2, 2016
    • Secondary endpoints revised (2)
    • Study description expanded, about 130 words
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Eligibility criteria expanded, about 4 words
    • Study sites: 0 to 1
    • Study title expanded, about 2 words
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of adverse events
Timeframe: up to 72 months

Secondary (2)

Trends in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS-IV-Preschool, ADHD-RS-IV or ADHD-RS-5) Score
Trends in Clinical Global Impression-Improvement (CGI-I) scale score

Arms and interventions

Open-Label TreatmentExperimental

Cohort 'A': Children and adolescents, 6-17 years of age, who completed a Phase 2 (Study 812P202) or Phase 3 (Study 812P301, 812P302, 812P303, or 812P304) randomized, double-blind, placebo-controlled clinical trial. Cohort 'B': Preschool-age children, 4-5 years of age, who completed a Phase 4 (Study 812P401) randomized, double-blind, placebo-controlled clinical trial.

Drugs: SPN-812

Sites

16 sites in 1 country